In Vitro and In Vivo Evaluation of a Novel Nonscrotal Matrix-Type Transdermal Delivery System of Testosterone

2005 ◽  
Vol 31 (3) ◽  
pp. 257-261 ◽  
Author(s):  
Hong Zhao ◽  
Chi-Ho Lee ◽  
Suk-Jae Chung ◽  
Chang-Koo Shim ◽  
Dae-Duk Kim
Keyword(s):  
Delivery System ◽  
Transdermal Delivery ◽  
In Vivo Evaluation ◽  
Matrix Type ◽  
Transdermal Delivery System

In Vitro and In Vivo Evaluation of a Novel Nonscrotal Matrix-Type Transdermal Delivery System of Testosterone

2005 ◽  
Vol 31 (3) ◽  
pp. 257-261 ◽  
Author(s):  
Hong Zhao ◽  
Chi-Ho Lee ◽  
Suk-Jae Chung ◽  
Chang-Koo Shim ◽  
Dae-Duk Kim
Keyword(s):  
Delivery System ◽  
Transdermal Delivery ◽  
In Vivo Evaluation ◽  
Matrix Type ◽  
Transdermal Delivery System

scholarly journals Characterization of Temperature Profiles in Skin and Transdermal Delivery System When Exposed to Temperature Gradients In Vivo and In Vitro

2017 ◽  
Vol 34 (7) ◽  
pp. 1491-1504 ◽  
Author(s):  
Qian Zhang ◽  
Michael Murawsky ◽  
Terri LaCount ◽  
Jinsong Hao ◽  
Gerald B. Kasting ◽  
...  
Keyword(s):  
Delivery System ◽  
Transdermal Delivery ◽  
Temperature Gradients ◽  
Temperature Profiles ◽  
Transdermal Delivery System

scholarly journals DEVELOPMENT AND CHARACTERIZATION OF TRANSDERMAL DELIVERY SYSTEM OF DOXAZOSIN MESYLATE

2019 ◽  
Vol 11 (1) ◽  
pp. 43 ◽  
Author(s):  
Madhur Kulkarni ◽  
Vishakha Hastak ◽  
Supriya Jadhav
Keyword(s):  
Delivery System ◽  
Transdermal Delivery ◽  
Skin Irritation ◽  
Stability Studies ◽  
Accelerated Stability ◽  
In Vitro Permeation ◽  
Folding Endurance ◽  
Transdermal Delivery System

Objective: The study involved development of transdermal delivery system (TDDS) of doxazosinmesylate (doxa) to achieve effective systemic delivery of the drug.Methods: TDDS of doxa was prepared using hydroxypropyl methyl cellulose (HPMC) K100LV and polyvinyl pyrrolidone (PVP) K30 in 3:1 ratio solvent casting method. The formulation was evaluated for folding endurance, moisture uptake, pH, drug content and in vitro permeation. Various permeation enhancers were incorporated at 5% w/w concentration into the patch formulationto study their impact on the drug permeation. The TDDS made with Transcutol® as an enhancer was subjected to accelerated stability studies and in vivo skin irritation studies.Results: The developed TDDS showed folding endurance of 170, moisture uptakeof 15.7%, pH of 6.3, and drug content of 99±1.1% and 66% in vitro permeation of doxa over 24h. The effect of various enhancers expressed in terms of average flux can be summarized as Transcutol® (10.6±2.1 µg/cm2h)>dimethyl sulfoxide(10.17±1.2 µg/cm2h)>benzyl alcohol (9.55±1.3 µg/cm2h)>no enhancer (8.86±1.1 µg/cm2h)>dimethyl isosorbide (8.21±1.5 µg/cm2h)>Isostearic acid (7.82±1.4 µg/cm2h)>propylene carbonate (7.67±1.4 µg/cm2h)>oleic acid (7.12 µg±0.8/cm2h). The formulation was found to be stable during the accelerated stability studies. In vivo studies indicated absence of skin irritation effect the TDDS containing Transcutol®.Conclusion: TDDS of doxa comprising HPMC K100LV and PVPK30 in the ratio of 3:1 and 5% Transcutol® could serve as a potential TDDS in the treatment of benign prostatic hyperplasia (BPH) and hypertension.

Development of tizanidine loaded aspasomes as transdermal delivery system: ex-vivo and in-vivo evaluation

2019 ◽  
pp. 1-11 ◽  
Author(s):  
Rawia M. Khalil ◽  
Ahmed Abdelbary ◽  
Silvia Kocova El Arini ◽  
Mona Basha ◽  
Hadeer A. El-Hashemy ◽  
...  
Keyword(s):  
Delivery System ◽  
Transdermal Delivery ◽  
Ex Vivo ◽  
In Vivo Evaluation ◽  
Transdermal Delivery System
Sign in / Sign up

Export Citation Format

Share Document